Compare AstraZeneca plc (AZN) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Lithium Americas Corp — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Lithium Americas Corp trades at $3.32 (market cap $1.18B). The key difference: AstraZeneca plc is far larger — about 210.3× Lithium Americas Corp's market cap, and AstraZeneca plc pays a 2.01% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| AZN | LAC | |
|---|---|---|
Market Cap | $248.14B | $1.18B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $10.05 |
52-Week Low | $147.06 | $2.71 |
Enterprise Value | $275.41B | $1.29B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Lithium Americas (LAC) trades at $3.26, showing modest daily gains of 0.31%. The stock exhibits a bullish technical signal with mixed quarterly earnings performance, beating estimates twice but missing significantly in Q4 2025. Recent $175 million financing strengthens the balance sheet as Thacker Pass approaches peak construction. The company maintains negative profitability metrics with ROE at -11.35% but trades below book value at P/B of 0.88.
Investment outlook remains speculative with significant execution risk at Thacker Pass requiring substantial capital expenditures. Analyst consensus leans cautious with 47% buy ratings versus 53% holds. Positive catalysts include lithium demand growth and government support, but cash burn and dilution risks persist for equity holders amid ongoing development phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
